Literature DB >> 19067122

Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha, and their responsive genes in the liver of apoE and LDLR double deficient mice.

Yanyan Zou1, Hui Du, Miao Yin, Liang Zhang, Liufeng Mao, Ning Xiao, Guocheng Ren, Cong Zhang, Jie Pan.   

Abstract

The significance of transcription factors PPAR alpha, LXR alpha, and their responsive/target genes for the pathogenesis of atherosclerosis in apolipoprotein E and low-density lipoprotein receptor double deficient (AL) mice fed with high fat and cholesterol (HF) diet were studied. C57BL/6J wild-type (WT) mice were used as control to the AL mice. Plasma lipid metabolites and morphological atherosclerotic lesions in aortic wall were determined. Semi- and real-time quantitative RT-PCR were used to measure gene expression patterns between AL mice and the controls, which were fed with HF or normal chow diet. The results showed that in AL mice fed with HF diet, plasma lipid levels, hepatic lipid accumulation, and atherogenesis together with upregulated PPAR alpha, LXR alpha, and their target genes, i.e., FAT, SCD1, FAS, Angptl3, and apoB100 significantly increased in a 12-week long feeding period. In contrast, apoAI, apoAIV, apoF, LPL, and SR-BI were decreased compared to chow-fed group. In WT mice, PPAR alpha, LXR alpha, FAS, Angpt13, CPT1, apoF, ACOX1, LPL, and SR-BI were increased with HF treatment, while apoAI and apoAIV were decreased markedly. The different changes of lipid metabolism-related genes between AL and WT mice, fed with HF diet or chow diet indicated that the mechanisms of dietary effects on gene mutant mice are different from those of intact WT mice. Since lipid metabolic system defected genetically in AL mice, we suggest that the changes of PPAR alpha, LXR alpha, and their target genes aggravated lipid metabolic disorder in the liver and further accelerated the development of atherosclerosis on a stress of HF diet feeding in AL mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067122     DOI: 10.1007/s11010-008-9982-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  43 in total

1.  Insulin resistance syndrome and dyslipidemia.

Authors:  Ronald M Krauss
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

2.  Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.

Authors:  Mitsuru Shimamura; Morihiro Matsuda; Hiroaki Yasumo; Mitsuyo Okazaki; Kazunori Fujimoto; Keita Kono; Tetsuya Shimizugawa; Yosuke Ando; Ryuta Koishi; Takafumi Kohama; Naohiko Sakai; Kazuaki Kotani; Ryutaro Komuro; Tatsuo Ishida; Kenichi Hirata; Shizuya Yamashita; Hidehiko Furukawa; Iichiro Shimomura
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

Review 3.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

4.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels.

Authors:  K F Kozarsky; M H Donahee; A Rigotti; S N Iqbal; E R Edelman; M Krieger
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

5.  Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta.

Authors:  Y Zhang; J J Repa; K Gauthier; D J Mangelsdorf
Journal:  J Biol Chem       Date:  2001-09-18       Impact factor: 5.157

6.  Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.

Authors:  B Föger; M Chase; M J Amar; B L Vaisman; R D Shamburek; B Paigen; J Fruchart-Najib; J A Paiz; C A Koch; R F Hoyt; H B Brewer; S Santamarina-Fojo
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

7.  Analysis of low-density lipoprotein catabolism by primary cultures of hepatic cells from normal and low-density lipoprotein receptor knockout mice.

Authors:  T Q Truong; A Auger; F Denizeau; L Brissette
Journal:  Biochim Biophys Acta       Date:  2000-04-12

Review 8.  PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.

Authors:  Andrew C Li; Christopher K Glass
Journal:  J Lipid Res       Date:  2004-10-16       Impact factor: 5.922

Review 9.  Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis.

Authors:  Mercedes Ricote; Annabel F Valledor; Christopher K Glass
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-30       Impact factor: 8.311

10.  Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements.

Authors:  Lauren M Cagen; Xiong Deng; Henry G Wilcox; Edwards A Park; Rajendra Raghow; Marshall B Elam
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

View more
  12 in total

1.  Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism.

Authors:  Yan Liu; Richard E Morton
Journal:  Curr Opin Lipidol       Date:  2020-08       Impact factor: 4.776

Review 2.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

3.  Supplementation with an insoluble fiber obtained from carob pod (Ceratonia siliqua L.) rich in polyphenols prevents dyslipidemia in rabbits through SIRT1/PGC-1α pathway.

Authors:  María Valero-Muñoz; Sandra Ballesteros; Baltasar Ruiz-Roso; Lourdes Pérez-Olleros; Beatriz Martín-Fernández; Vicente Lahera; Natalia de Las Heras
Journal:  Eur J Nutr       Date:  2017-12-22       Impact factor: 5.614

4.  Lipid abnormalities in alpha/beta2-syntrophin null mice are independent from ABCA1.

Authors:  Tobias Hebel; Kristina Eisinger; Markus Neumeier; Lisa Rein-Fischboeck; Rebekka Pohl; Elisabeth M Meier; Alfred Boettcher; Stanley C Froehner; Marvin E Adams; Gerhard Liebisch; Sabrina Krautbauer; Christa Buechler
Journal:  Biochim Biophys Acta       Date:  2015-01-24

Review 5.  ANGPLT3 in cardio-metabolic disorders.

Authors:  Xin Su
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

6.  Obesity and lipid stress inhibit carnitine acetyltransferase activity.

Authors:  Sarah E Seiler; Ola J Martin; Robert C Noland; Dorothy H Slentz; Karen L DeBalsi; Olga R Ilkayeva; Jie An; Christopher B Newgard; Timothy R Koves; Deborah M Muoio
Journal:  J Lipid Res       Date:  2014-01-06       Impact factor: 5.922

7.  Dietary cholesterol promotes growth and ecdysone signalling pathway by modulating cholesterol transport in swimming crabs (Portunus trituberculatus).

Authors:  Tingting Zhu; Qicun Zhou; Zheng Yang; Yingying Zhang; Jiaxiang Luo; Xiangsheng Zhang; Yuedong Shen; Lefei Jiao; Douglas R Tocher; Min Jin
Journal:  Anim Nutr       Date:  2022-05-19

8.  Triptolide inhibits the progression of atherosclerosis in apolipoprotein E-/- mice.

Authors:  Longfeng Luo; Tianlun Yang
Journal:  Exp Ther Med       Date:  2016-08-24       Impact factor: 2.447

9.  PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

Authors:  Yunpeng Qi; Changtao Jiang; Naoki Tanaka; Kristopher W Krausz; Chad N Brocker; Zhong-Ze Fang; Bryce X Bredell; Yatrik M Shah; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-17       Impact factor: 4.052

10.  Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis.

Authors:  Marian Kampschulte; Christiane Stöckl; Alexander C Langheinrich; Ulrike Althöhn; Rainer M Bohle; Gabriele A Krombach; Philipp Stieger; Yuri Churin; Sandra Kremer; Christian Dierkes; Timo Rath; Elke Roeb; Martin Roderfeld
Journal:  Lab Invest       Date:  2014-09-08       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.